[Skip to Navigation]
August 1962


Author Affiliations

Scientific Director Allergan Pharmaceuticals Santa Ana, Calif.

Arch Ophthalmol. 1962;68(2):300. doi:10.1001/archopht.1962.00960030304030

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:  —After reading Dr. Kaufman's solicited comments on my letter to you, I feel, in the interest of clarity, that some additional statements should be made.I certainly have no quarrel with Dr. Kaufman's position that IDU represents a significant advance in the therapy of herpetic keratitis. Indeed, studies with our own preparation of IDU certainly tend to support the therapeutic findings presented in his article with Drs. Nesburn and Maloney in the May issue of the Archives.In defense of my comment that IDU inhibits both viral and cellular DNA, I should like to call attention to Dr. Kaufman's statement in his article (p. 590) where he points out that after all, "this drug was developed because of possible cytotoxic properties"; therefore, the logical assumption is that it does affect cellular DNA. In order to inhibit effectively the abnormally large amount of DNA being synthesized within a

First Page Preview View Large
First page PDF preview
First page PDF preview
Add or change institution